MRK Oct 2024 135.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:02PM EDT. Market open.
| Previous close | 4.9000 |
| Open | 5.1000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 135.00 |
| Expiry date | 2024-10-18 |
| Day's range | 4.9000 - 5.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 429 |
Business WireMerck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
RAHWAY, N.J., May 01, 2024--Merck Announces KEYNOTE-811 Trial Met Dual Primary Endpoint as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or GEJ Cancer
Insider MonkeyMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.07, expectations were $1.94. Merck & Co., Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […]
Business WireMerck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
RAHWAY, N.J., April 29, 2024--Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
© 2024 Yahoo. All rights reserved.